image
Healthcare - Medical - Devices - NASDAQ - US
$ 14.36
-1.51 %
$ 560 M
Market Cap
-4.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OFIX stock under the worst case scenario is HIDDEN Compared to the current market price of 14.4 USD, Orthofix Medical Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OFIX stock under the base case scenario is HIDDEN Compared to the current market price of 14.4 USD, Orthofix Medical Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one OFIX stock under the best case scenario is HIDDEN Compared to the current market price of 14.4 USD, Orthofix Medical Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OFIX

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
799 M REVENUE
7.08%
-84.6 M OPERATING INCOME
39.17%
-126 M NET INCOME
16.78%
25.8 M OPERATING CASH FLOW
156.37%
-27.6 M INVESTING CASH FLOW
16.75%
50.7 M FINANCING CASH FLOW
-22.37%
216 M REVENUE
9.69%
-6.44 M OPERATING INCOME
65.90%
-29.1 M NET INCOME
-6.42%
23.7 M OPERATING CASH FLOW
103.32%
-1.14 M INVESTING CASH FLOW
80.64%
31.5 M FINANCING CASH FLOW
1382.04%
Balance Sheet Orthofix Medical Inc.
image
Current Assets 433 M
Cash & Short-Term Investments 83.2 M
Receivables 135 M
Other Current Assets 215 M
Non-Current Assets 460 M
Long-Term Investments 0
PP&E 140 M
Other Non-Current Assets 320 M
9.32 %15.08 %24.11 %15.65 %35.85 %Total Assets$893.3m
Current Liabilities 169 M
Accounts Payable 48.8 M
Short-Term Debt 4.78 M
Other Current Liabilities 115 M
Non-Current Liabilities 222 M
Long-Term Debt 175 M
Other Non-Current Liabilities 46.7 M
12.51 %29.49 %44.81 %11.97 %Total Liabilities$390.2m
EFFICIENCY
Earnings Waterfall Orthofix Medical Inc.
image
Revenue 799 M
Cost Of Revenue 254 M
Gross Profit 546 M
Operating Expenses 631 M
Operating Income -84.6 M
Other Expenses 41.4 M
Net Income -126 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)799m(254m)546m(631m)(85m)(41m)(126m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.28% GROSS MARGIN
68.28%
-10.58% OPERATING MARGIN
-10.58%
-15.49% NET MARGIN
-15.49%
-24.62% ROE
-24.62%
-13.87% ROA
-13.87%
-11.80% ROIC
-11.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Orthofix Medical Inc.
image
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -126 M
Depreciation & Amortization 76 M
Capital Expenditures -34.9 M
Stock-Based Compensation 32.5 M
Change in Working Capital 0
Others 41.4 M
Free Cash Flow -9.09 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Orthofix Medical Inc.
image
Wall Street analysts predict an average 1-year price target for OFIX of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OFIX Lowest Price Target Wall Street Target
24 USD 67.13%
OFIX Average Price Target Wall Street Target
24 USD 67.13%
OFIX Highest Price Target Wall Street Target
24 USD 67.13%
Price
Max Price Target
Min Price Target
Average Price Target
2424222220201818161614141212May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Orthofix Medical Inc.
image
Sold
0-3 MONTHS
94.3 K USD 2
3-6 MONTHS
427 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT. businesswire.com - 1 month ago
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. globenewswire.com - 1 month ago
Orthofix Announces Appointment of Vickie Capps to Board of Directors LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously. businesswire.com - 1 month ago
Orthofix to Participate in the 37th Annual Roth Conference LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Posti. businesswire.com - 1 month ago
Orthofix (OFIX) Q4 Earnings Lag Estimates Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago. zacks.com - 1 month ago
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 202. businesswire.com - 1 month ago
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 9:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.co. businesswire.com - 2 months ago
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations. businesswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX). Investors who purchased Orthofix securities prior to October 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OFIX. accesswire.com - 4 months ago
Orthofix to Participate in Upcoming Investor Conferences LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Stifel 2024 Healthcare Conference in New York, NY, November 18, 2024, fireside chat at 8:35 AM Eastern Time Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach, CA, December 9, 2024,. businesswire.com - 5 months ago
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript Orthofix Medical Inc. (NASDAQ:OFIX ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix Third Quarter 2024 Earnings Call. I am Fran, and I'll be the operator assisting you today. seekingalpha.com - 5 months ago
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX) and certain current and former officers and directors of Orthofix and SeaSpine Holdings Corporation ("SeaSpine"). globenewswire.com - 5 months ago
8. Profile Summary

Orthofix Medical Inc. OFIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 560 M
Dividend Yield 0.00%
Description Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact 3451 Plano Parkway, Lewisville, TX, 75056 https://www.orthofix.com
IPO Date April 24, 1992
Employees 1616
Officers Ms. Julie D. Dewey Chief Investor Relations & Communications Officer Mr. Geoffrey C. Gillespie Vice President & Corporate Controller Ms. Julie B. Andrews Chief Financial Officer Ms. Stephanie Walsh Chief Human Resources Officer Ms. Aviva McPherron President of Global Operations & Quality Mr. Massimo Calafiore President, Chief Executive Officer, Director and Interim President of Global Spine Mr. Ehab M. Esmail Senior Vice President of Global Quality, Regulatory & Clinical Affairs Mr. Tyler P. Lipschultz President of Global Biologics Mr. J. Andres Cedron Chief Legal Officer & Corporate Secretary Ms. Jill Mason Chief Compliance & Risk Officer